Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tercica v. Insmed

Executive Summary

Tercica filed an unfair business practices suit Dec. 6 in San Francisco federal court alleging that Insmed engaged in false and deceptive practices and promotions in claiming that Tercica's growth therapy Increlex is unsafe and that its own investigational therapy iPlex is safer. The lawsuit is the latest step in a competitive showdown between the two companies and comes as the Dec. 12 user fee date for iPlex (mecasermin rinifibate) approaches. Increlex (mescasermin [rDNA origin]) cleared FDA in August with seven years of orphan drug exclusivity (1"The Pink Sheet" Sept. 5, 2005, p. 19). In addition to monetary relief, Tercica requests that the court stop Insmed from making false statements and order the company to publicly correct alleged misrepresentations. Insmed said the suit is unwarranted...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel